Forty eight hospitals that lost their eligibility for 340B drug discounts for reasons related to the COVID-19 pandemic are seeking reinstatement to the 340B program.

48 Hospitals Seek Readmission to 340B After Losing Eligibility Due to COVID-19 Pandemic

At least 48 hospitals lost their eligibility for 340B drug discounts for reasons related to the COVID-19 pandemic and are seeking reinstatement to the 340B program, the U.S. Health Resources and Services Administration (HRSA) said this week.

April 14 was the deadline for such hospitals that want to reenroll in 340B to attest to HRSA that the public health emergency (PHE) disrupted their admission patterns to the point that their Medicare disproportionate share (DSH) adjustment percentage fell below the level needed to qualify for 340B drug pricing. Congress passed a spending bill last month with language to help such hospitals get back into 340B and others that similarly may lose their eligibility through the end of this year.

At least 48 hospitals lost their eligibility for 340B drug discounts for reasons related to the COVID-19 pandemic and are seeking reinstatement to the 340B program, HRSA says.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report